New drug combo could make stem cell transplants safer for blood cancer patients
NCT ID NCT07044544
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This early-stage trial tests whether adding two drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant is safe for people with high-risk blood cancers like leukemia. The study involves 20 adults aged 18-75 who have a matched donor. The main goal is to check for severe side effects, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine and Venetoclax (drugs added to standard transplant chemotherapy)
What this could lead to
If successful, this could lead to a safer and more effective transplant approach for people with high-risk blood cancers, potentially improving long-term control of the disease.
What could go wrong
This is a very early phase 1 trial with only 20 participants, so the main goal is safety, not effectiveness. The added drugs may cause severe side effects or not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.